Welcome to the news from the world of the ReMuS registry, which monitors the course of multiple sclerosis in the Czech Republic. Here we focus mainly on news, research and information that is directly related to the registry and its results. Although we cannot contribute new content every day, we believe you will find valuable and relevant information here.
Our registry participated in the 41st ECTRIMS Congress, which took place on 24-26 September 2025 at the Barcelona International Convention Center (CCIB). This largest global event in the field of multiple sclerosis brought together top [...]
ReMuS Press Conference | 28 May 2025 On the occasion of World Multiple Sclerosis Day, the ReMuS and IMPULS foundations held a traditional press conference on Wednesday 28 May 2025 from 10.00 [...]
ReMuS in America - a poster at the prestigious American Academy of Neurology Congress In April 2025, the AAN Congress took place, where Dr. Dominika Št'astná presented the results of the [...]
Get to know the ReMuS Registry For the presentation of the ReMuS Registry at the ECTRIMS International Congress on Neuroimmunological Diseases, we have prepared a short presentation that will reveal what is hidden under the hood of this [...]
A new study published in the Journal of Central Nervous System Disease provides insights into the efficacy of cladribine in the treatment of multiple sclerosis (MS) in real-world clinical practice. The paper uses data from the Czech nationwide ReMuS registry and...
The 1st Neuro-Ophthalmology Forum, held on June 20, 2024 in Prague. This congress was an important step towards deepening collaboration between neurologists and ophthalmologists. Our aim was not only to share expertise but also to develop a multidisciplinary approach in the care of patients with neuro-ophthalmological problems.
If a person becomes ill with multiple sclerosis (MS), it should not matter whether they live in Cheb, Kolín or Frýdek Místek. The same care should be provided in all centres throughout the Czech Republic. Thanks to the Patient Register...
Article doc. Anna Glaser from Karolinska Institutet, Sweden, focuses on the importance and contribution of European multiple sclerosis registries, specifically the Big Multiple Sclerosis Data Network (BMSD) project, in which ReMuS is actively involved...
On Friday 3 November, the 5th workshop for doctors, nurses and registry administrators from all RS centres in the Czech Republic took place. In the Hermitage Hotel in Prague, the topics covered included safety monitoring using the MedDRA system, ongoing projects...
On the stage of the refectory of Emmaus Abbey, during one evening in November, all those who were not only at the birth of the ReMuS registry, but also its successors, gathered. Musical accompaniment was provided by singer Katerina Marie Tichá with her band Bandjeez and guests.
In their new study, a team led by Richard Nicholas looked at how health systems in different countries influence clinical diagnosis and access to treatment for multiple sclerosis...
The original article by Pavel Hradílek, M.D., Ph.D. from the University Hospital Ostrava based on the ReMuS registry data was published in the journal Multiple Sclerosis and Related Disorders. Because the influence of breastfeeding and its duration on the course of multiple sclerosis is unclear, the authors analyzed real data on breastfeeding women with MS and the course of their disease...
Expert article by Ing. Tereza Hrnčiarová, Ph.D. from the 1st Medical Faculty of Charles University deals with the issue of treatment strategies in relapsing-remitting multiple sclerosis. Her work is based on data from the Czech ReMuS registry and the Swedish SMSR (Swedish MS Registry). It builds on the...
To mark the approaching World Multiple Sclerosis (MS) Day, the ReMuS Patient Registry held its traditional press conference on 25 May 2023. The conference presented the most up-to-date data on MS and the practical achievements that the ReMuS Registry has been able to implement during its 10 years of existence...
Multiple sclerosis is a serious neuroimmunological disease and data on its incidence and treatment are systematically and longitudinally evaluated by the national ReMuS registry. Trends in the treatment of patients in the Czech Republic were discussed by Dominika Št'astná, M.D., Ph.D. from the General University Hospital in Prague in her...
Secondary progressive multiple sclerosis (SPRS) represents an important stage in the development of multiple sclerosis, but is often difficult to diagnose accurately. A study conducted in five European countries used objective classifiers to determine the proportion and characteristics of SPRS in different registries of multiple sclerosis patients, including the national ReMuS registry. The findings suggest ...
In a recent study published in Multiple Sclerosis and Related Disorders, researchers examined the risk of relapse in patients with multiple sclerosis (MS) and neuromyelitis optica (NMOSD) after vaccination against COVID-19 and after undergoing COVID-19. The study looked at data from the Czech national ReMuS registry and showed...
Multiple sclerosis can also affect children, although it is a rarer form of the disease. Approximately 3-10 % patients will develop multiple sclerosis before the age of 16. This study focuses on the analysis of a group of pediatric patients with relapsing form of multiple sclerosis who started treatment...
Pregnancy in patients with multiple sclerosis (MS) requires special care, particularly with regard to decisions regarding disease-modifying disease (DMD) treatment and counselling regarding the period of conception, pregnancy and the postpartum period. This study aims to analyze the impact of pregnancy, childbirth or miscarriage on the course of multiple sclerosis ...
The emergence of the novel coronavirus COVID-19 has raised concerns about the course of this disease in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the incidence, severity, and risk factors for a more severe course of COVID-19 among patients with MS and NMOSD ...
Exactly 1,918 patients with multiple sclerosis (MS) who have also contracted coronavirus are being closely monitored by doctors in the ReMuS Multiple Sclerosis Patient Registry. Since March last year, they have been investigating the symptoms, treatment and possible impact of coronavirus on this specific group of people. Initial analyses show that MS is not a risk factor, but patients who are older, have more severe neurological impairment, are obese and also have some type of chronic therapy are at higher risk...
This study focuses on the description of treatment interruptions and discontinuations in the Big Multiple Sclerosis Data Network registry group. This cohort study, led by Prof. Jan Hillert from Karolinska Institutet, Sweden, pooled data from five clinical registries covering a period of 20 years....
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. After the first demyelinating episode, well-established drugs are commonly used in MS patients in the Czech Republic...
In a review article of the professional journal Neurology for Practice, the expert guarantor of the ReMuS registry focused on the introduction of the ReMuS registry and especially the range of data contained in it. The article also offers insight into the representation of patients in individual MS centres in the Czech Republic, the development of the deployment of highly effective drugs or the very important area of...
A new article in the professional journal Remedia provides information on what can be found in the data of the ReMuS multiple sclerosis patient registry and in real clinical practice in the Czech Republic after six years of operation. Since its inception, the records are available...
Proper management of multiple sclerosis (MS) treatment requires feedback from clinical practice provided by registries. This article focuses on the introduction of the Czech national multiple sclerosis registry, ReMuS, and examines the availability and use of drugs...
In the five years of its existence, the Czech national registry of multiple sclerosis patients, ReMuS, has become an invaluable source of data for clinical practice and research. This article provides an overview of how the registry has evolved since its inception in 2013...
In 2018, an updated mapping of multiple sclerosis (MS) registries in Europe was conducted, building on a previous survey from 2014. This survey covers 19 registries, mostly from Europe, and provides detailed information on the organisation, data collection methods, quality of control mechanisms and funding ...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. Interferon (IFN) β-1a 44 μg, dimethyl fumarate (DMF), and fingolimod are established drugs for the treatment of relapsing-remitting MS (RR MS). The aim of this project, which involves analysis of data from the ReMuS registry, was to compare ...
Article doc. Dana Horáková published in Multiple Sclerosis News offers a detailed look at the creation and development of the Czech national registry of multiple sclerosis patients, ReMuS, since its establishment in 2013. The reader will find information about the structure of the registry, the process of data collection,...